Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Non-cash Items (2016 - 2025)

Historic Non-cash Items for Bio-Techne (TECH) over the last 13 years, with Q2 2025 value amounting to $155.0 million.

  • Bio-Techne's Non-cash Items rose 178840.16% to $155.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was $155.0 million, marking a year-over-year increase of 178840.16%. This contributed to the annual value of $155.0 million for FY2025, which is 7925.87% down from last year.
  • As of Q2 2025, Bio-Techne's Non-cash Items stood at $155.0 million, which was up 178840.16% from $8.2 million recorded in Q2 2024.
  • In the past 5 years, Bio-Techne's Non-cash Items registered a high of $155.0 million during Q2 2025, and its lowest value of $7.1 million during Q2 2021.
  • Moreover, its 5-year median value for Non-cash Items was $8.2 million (2024), whereas its average is $37.3 million.
  • Per our database at Business Quant, Bio-Techne's Non-cash Items tumbled by 501.1% in 2024 and then skyrocketed by 178840.16% in 2025.
  • Quarter analysis of 5 years shows Bio-Techne's Non-cash Items stood at $7.1 million in 2021, then grew by 10.49% to $7.8 million in 2022, then increased by 10.82% to $8.6 million in 2023, then dropped by 5.01% to $8.2 million in 2024, then soared by 1788.4% to $155.0 million in 2025.
  • Its last three reported values are $155.0 million in Q2 2025, $8.2 million for Q2 2024, and $8.6 million during Q2 2023.